Category: Oral MS Medications

Oral Laquinimod For MS Treatment Significantly Reduced Disease Activity And Disability Progression While Providing Good Safety And Tolerability

April 12, 2011 Teva Pharmaceutical Industries Ltd. and Active Biotech announced today results from the two-year Phase III ALLEGRO study…

Stuart Schlossman

Biogen Oral MS Pill Meets Goals of Study

April 11, 2011 By THOMAS GRYTA Biogen Idec Inc.’s oral drug for multiple sclerosis showed success in the first of two large…

Stuart Schlossman

Media Release: Novartis therapy GilenyaTM reduced the risk of MS disability progression regardless of disease severity

Novartis therapy GilenyaTM reduced the risk of MS disability progression regardless of treatment history or disease severity, new analysis shows…

Stuart Schlossman

Gilenya Update

written by: Cherie C. Binns RN BS MSCN April 4, 2011 I attended a patient education program on Gilenya today presented…

Stuart Schlossman

Neurologists Anticipate Increased Use of Novartis’ Gilenya and Biogen Idec’s Tysabri over the Next Six Months Despite Safety Concerns Surrounding Both Products

March 30, 2011 EXTON, Pa.–(BUSINESS WIRE)–Physician trial and market share of Novartis’ Gilenya, the first oral disease modifying agent (DMA)…

Stuart Schlossman

Novartis Receives European Commission Approval For Gilenya(R), The First Oral Multiple Sclerosis Treatment For Use In The EU

March 22, 2011 The European Commission has granted Novartis approval for Gilenya® (fingolimod) 0.5 mg daily as a disease modifying…

Stuart Schlossman

Current MS Research News ( from a-z )

Source: MSRC-UK Please choose one of the news categories below. New Discoveries Drugs Research MS Knowledge Research Paediatric Multiple Sclerosis Research…

Stuart Schlossman

US seeks more data on MS treatment, Oral Cladribine

Bloomberg News – March 3, 2011 ZURICH — Merck KGaA failed to win US regulators’ backing for its multiple sclerosis pill cladribine,…

Stuart Schlossman

FDA Turns Down Cladribine for MS

By John Gever, Senior Editor, MedPage Today Reviewed by  March 02, 2011 Review The FDA said it won’t approve the…

Stuart Schlossman

Novartis gains approval for Gilenya® as a first-line disease modifying oral therapy for multiple sclerosis in Switzerland and Australia

January 24, 2011 * Gilenya offers an alternative to frequent injections, which is a major advance for people with relapsing-remitting…

Stuart Schlossman

Categories

Latest Blog Posts